Core Viewpoint - The article emphasizes the increasing urgency for effective antiviral interventions in response to the rising influenza activity, particularly among children and adolescents, highlighting the role of innovative biopharmaceutical solutions from companies like Sinovac Biotech in combating respiratory viral infections [1][12]. Group 1: Antiviral Strategies - Influenza, caused by the influenza virus, spreads rapidly, necessitating early activation of the body's immune defenses, with interferon serving as a natural first line of defense against viral infections [2]. - Human interferon α1b, a domestically developed type I interferon, exhibits broad-spectrum antiviral activity and mild immunomodulatory properties, with Sinovac being one of the early companies engaged in its research and production [2]. Group 2: Clinical Applications of Interferon - Interferon plays a crucial role in treating viral respiratory infections, with early intervention being emphasized as key to effective antiviral therapy [3]. - The clinical use of Sinovac's interferon α1b (brand name: Sai Ruojin) has been validated over three decades, particularly in treating viral pneumonia and bronchiolitis in children, demonstrating efficacy in controlling viral load and alleviating symptoms [5]. Group 3: Innovation in Antiviral Solutions - Sinovac is advancing the development of GB05, an inhalation solution of human interferon α1b, aimed at addressing the limitations of injection methods for respiratory infections, particularly for conditions like respiratory syncytial virus (RSV) [9][10]. - GB05 features molecular design innovations that enhance stability and safety, making it suitable for pediatric use, and its delivery method allows for targeted action in the respiratory tract while minimizing systemic exposure [10]. Group 4: Commitment to Quality and Social Responsibility - Sinovac prioritizes drug quality through a stringent quality management system, ensuring effective clinical outcomes from the development process to final product [8]. - The company engages in academic exchanges to promote the rational use of interferon, emphasizing early and adequate treatment principles to improve the management of viral respiratory infections in primary healthcare settings [8]. Group 5: Future Directions - The article concludes that flu prevention requires a multifaceted approach, and Sinovac is committed to continuous innovation in antiviral drug development to meet unmet clinical needs, contributing to public health initiatives [12].